Webinar
Replay
Conquer the complexity
of biology with clinical
trial simulations
trial simulations
Accelerate and derisk
Reduce the duration and number of experiments
Reduce risk to human subjects through improved trial design
Significantly reduce clinical trial burden by using simulations
Our success stories
« We are applying jinkō’s virtual population simulation technology and in silico research approach as a complement to clinical development plans to support health technology assessment for our innovative therapies. »
Apply for a new marketing authorization and present new results to demonstrate the higher efficacy of Natpar compared to the standard of care.
Reduce payer uncertainty to speed up acceptance and allow rare disease patients to access Natpar earlier.
« Generating such insights upstream, within a few months instead of many years, reduces risk and directs more successful drug development strategies. »
Pietro Scalfaro
Chief Medical Officer
Pietro Scalfaro
Chief Medical Officer
Find an efficient way to identify the best possible treatment combinations among
hundreds (if not thousands) of possibilities
Phase II
Disease model:
HBV
HBV
Treatment model:
Vonafexor (FXR agonist)
Vonafexor (FXR agonist)
Assessing Vonafexor’s efficacy in combination with different SoC regimens in +700 different trial designs
to identify the best protocol for ENYO’s next clinical trial
jinkō
the first collaborative clinical trial simulation platform
Combining the powers of data science, biology and medicine, jinkō predicts
clinical outcomes before trials in human subjects
Manage your knowledge and stay up to date through collaborative curation
Design and simulate with best-in-class model library, virtual patients and simple protocol design
Analyze and derisk : intuitive interface
for clinical trial experts
Learn more
Solutions across R&D
Applications from discovery to market
Nature communications article
Nova’s modeling approach is rooted in systems biology and quantitative systems pharmacology. This paper describes how the model ran in silico clinical trial simulations with OM Pharma’s OM-85 as prophylaxis for respiratory tract infection (RTI) in virtual populations.
See more
